NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer

NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.

Read news story


NICE Talks podcasts

NICE Talks brings you the real life experiences of people working within the NHS, public health and social care.

You will hear the stories behind our work to improve care across the country through evidence-based guidance.

Press and media

Contact the press office: 07973 970 534 |